

Millendo Therapeutics, Inc. Logo

## Millendo Therapeutics to Present at the 2020 Webbush PacGrow Healthcare Virtual Conference

August 5, 2020

ANN ARBOR, Mich.--(BUSINESS WIRE)--Aug. 5, 2020-- [Millendo Therapeutics, Inc.](#) (Nasdaq: MLND), a clinical stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 2020 Webbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 12:35 p.m. EDT.

A live webcast of the presentation will be available on the Investors & Media section of Millendo's website at <http://investors.millendo.com>. A replay of the webcast will be archived on Millendo's website for 30 days following the presentation.

### About Millendo Therapeutics, Inc.

Millendo Therapeutics is a biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit [www.millendo.com](http://www.millendo.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200805005094/en/): <https://www.businesswire.com/news/home/20200805005094/en/>

### Millendo Investor Contact:

Connie Chang  
Millendo Therapeutics  
734-864-8006  
[chang@millendo.com](mailto:chang@millendo.com)

### Millendo Media Contact:

Julie Bane  
MacDougall  
617-821-1089  
[jbane@macbiocom.com](mailto:jbane@macbiocom.com)

Source: Millendo Therapeutics, Inc.